(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash. The deal adds to Bristol's CAR T-cell therapies, with Orbital's lead experimental candidate OTX-201 that is designed to target autoimmune diseases. CAR-T therapy involves genetically modifying a patient's own immune cells to better recognize and attack specific disease-causing cells in the body. "With the acquisition of Orbital Therapeutics…we have an incredible opportunity to make CAR T-cell therapy more efficient and accessible to more patients," said Lynelle B. Hoch, president, Cell Therapy Organization, at Bristol Myers. (Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
